I'm not in NEU any more, haven't been for a while, but it's good to see 2591 getting some clinical validation in a Ph II trial.
There was always the possibility that it was going to be the better asset, long term, than 2256. While I can understand the company had very limited resources a few years ago, I was always annoyed that it wasn't pushed harder at the time.
I also felt the deal with Acadia made it harder for Neuren to develop 2591, and that was a key reason I quit being an investor.
But I'm not here to gripe, to me it looks like now Neuren has the money in the bank (and ongoing royalties) to push 2591 into Phase III and you'll all find out whether it is the broad-based neurodevelopmental drug that it could be.
- Forums
- ASX - By Stock
- NEU
- Ann: Phase 2 trial shows significant improvements in Angelman
Ann: Phase 2 trial shows significant improvements in Angelman, page-53
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
BOE
Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan
NEU
Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
Add NEU (ASX) to my watchlist
|
|||||
Last
$16.15 |
Change
-0.940(5.50%) |
Mkt cap ! $2.064B |
Open | High | Low | Value | Volume |
$15.04 | $16.33 | $14.65 | $25.91M | 1.638M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 125 | $16.15 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$16.20 | 1500 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 125 | 16.150 |
1 | 1332 | 16.140 |
1 | 650 | 16.110 |
1 | 500 | 16.100 |
1 | 4108 | 16.090 |
Price($) | Vol. | No. |
---|---|---|
16.200 | 1500 | 1 |
16.290 | 10000 | 1 |
16.300 | 4108 | 1 |
16.340 | 4108 | 1 |
16.380 | 4108 | 1 |
Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |